Haematological Malignancy Clinical Trials

14 recruiting

Haematological Malignancy Trials at a Glance

16 actively recruiting trials for haematological malignancy are listed on ClinicalTrialsFinder across 6 cities in 9 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Glasgow, Leicester, and Bristol. Lead sponsors running haematological malignancy studies include Cancer Research UK, Monash University, and CellCentric Ltd..

Browse haematological malignancy trials by phase

Treatments under study

About Haematological Malignancy Clinical Trials

Looking for clinical trials for Haematological Malignancy? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Haematological Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Haematological Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 2

Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial

Haematological MalignancyBlood CancerFungal Infection+1 more
The University of Queensland104 enrolled7 locationsNCT06510699
Recruiting
Phase 1Phase 2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Acute Myeloid LeukemiaHaematological Malignancy
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

MalignancyGastric CancerSoft Tissue Sarcoma+8 more
Cancer Research UK30 enrolled17 locationsNCT06988475
Recruiting
Phase 2Phase 3

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Haematological MalignancySolid Tumour
Cancer Research UK825 enrolled27 locationsNCT05722886
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

MelanomaOvarian NeoplasmsColorectal Neoplasms+3 more
Cancer Research UK30 enrolled16 locationsNCT05768178
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

MalignancyMelanomaCancer+8 more
Cancer Research UK30 enrolled27 locationsNCT05770544
Recruiting
Not Applicable

Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Haematological Malignancy
IRCCS Azienda Ospedaliero-Universitaria di Bologna100 enrolled1 locationNCT06814405
Recruiting
Phase 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Advanced CancerSolid TumorHaematological Malignancy
Helsinki University Central Hospital250 enrolled5 locationsNCT05159245
Recruiting
Phase 2Phase 3

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

Haematological MalignancyHypogammaglobulinemia
Monash University300 enrolled7 locationsNCT05678621
Recruiting

Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment

Haematological MalignancySolid Tumor, Unspecified, Adult
Morten Ladekarl3,000 enrolled1 locationNCT05695638
Recruiting
Not Applicable

Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy

Haematological Malignancy
Centre Hospitalier Universitaire de Nice75 enrolled1 locationNCT05379738
Recruiting

Aplastic Anaemia and Other Bone Marrow Failure Syndromes Registry (AAR)

Hereditary Predisposition to Haematological Malignancy (HPHM)Aplastic AnaemiaVEXAS Syndrome+1 more
Monash University1,000 enrolled37 locationsACTRN12623000461695
Recruiting

COVID-19 Vaccine Efficacy in patients with Blood Cancer

COVID-19Bone Marrow TransplantHaematological Malignancy
Royal Brisbane and Women's Hospital50 enrolled1 locationACTRN12621000538842
Recruiting
Phase 2

Phase II study of myeloablative allogeneic transplantation using pegylated G-CSF mobilised peripheral blood stem cells.

Acute Graft Versus Host Disease following allogeneic peripheral blood stem cell transplant from am HLA identical sibling for a haematological malignancy.
A/Prof Geoff Hill47 enrolled1 locationACTRN12605000460606